Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
Taizhou, China, and Ingelheim, Germany – 30 May, 2012 – Today the research based pharmaceutical company Boehringer Ingelheim and Taizhou China Medical City in Jiangsu Province, China, announced the signing of an agreement for the establishment of a veterinary vaccine manufacturing plant. Under the terms of the agreement, the plant will be built in Taizhou China Medical City, a national pharmaceutical high-tech industry park. The total investment will be more than 55.5 million euro. Upon completion, the facility will become a leading manufacturer for veterinary vaccines in Asia. The signing of the agreement, following the launch of the Boehringer Ingelheim Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai, in March 2012 marks another major step by Boehringer Ingelheim to continue the expansion of its animal health business in China.
“The move underlines our long-term commitment to China”, said Hubertus von Baumbach, responsible for the Corporate Board Divisions Finance and Animal Health. “We are a global leader in animal health, particularly in the swine vaccine sector. With the signing of the joint venture agreement we commit ourselves to bring the entire value chain of our vaccine business to China: R&D, manufacturing and sales.”
“Taizhou China Medical City, with its favourable geographic location, sound investment environment and well qualified employees, among many other things, proves to be an ideal partner for Boehringer Ingelheim”, George Heidgerken, Senior Vice President Boehringer Ingelheim Animal Health.
Rong He, Senior Deputy Mayor of Taizhou, said: “The decision by Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, to establish an animal vaccine manufacturing base in Taizhou is far-sighted and of strategic importance.” The manufacturing site will produce swine and poultry vaccines for China and other Asian markets and will create job opportunities for more than 200 employees.
“The Animal Health business plays an important strategic role for Boehringer Ingelheim China,” said David Preston, country manager of Boehringer Ingelheim in China. “The vaccine manufacturing venture and the veterinary R&D center will become two driving forces behind our objective to be a leading player in the China animal health business.”
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.